These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2186819)

  • 1. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group.
    Creutzig U; Ritter J; Schellong G
    Blood; 1990 May; 75(10):1932-40. PubMed ID: 2186819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
    Vormoor J; Ritter J; Creutzig U; Schellong G
    Klin Padiatr; 1989; 201(4):227-32. PubMed ID: 2674529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group.
    Ritter J; Creutzig U; Schellong G
    Leukemia; 1992; 6 Suppl 2():59-62. PubMed ID: 1578943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
    Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
    Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
    Ritter J; Creutzig U; Schellong G
    Haematol Blood Transfus; 1990; 33():185-92. PubMed ID: 2182410
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prognostic significance of eosinophilia in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
    Creutzig U; Ritter J; Niederbiermann-Koczy G; Harbott J; Schellong G
    Klin Padiatr; 1989; 201(4):220-6. PubMed ID: 2674528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current results of cooperative AML therapy studies in children: BFM-78 and 83].
    Creutzig U; Ritter J; Budde M; Riehm H; Henze G; Lampert F; Gerein V; Müller-Weihrich S; Niethammer D; Spaar HJ
    Klin Padiatr; 1986; 198(3):183-90. PubMed ID: 3523024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83.
    Ritter J; Vormoor J; Creutzig U; Schellong G
    Med Pediatr Oncol; 1989; 17(3):202-9. PubMed ID: 2546027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.
    Creutzig U; Ritter J; Riehm H; Langermann HJ; Henze G; Kabisch H; Niethammer D; Jürgens H; Stollmann B; Lasson U
    Blood; 1985 Feb; 65(2):298-304. PubMed ID: 3881140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
    Creutzig U; Harbott J; Sperling C; Ritter J; Zimmermann M; Löffler H; Riehm H; Schellong G; Ludwig WD
    Blood; 1995 Oct; 86(8):3097-108. PubMed ID: 7579404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a curative treatment within the AML-BFM studies.
    Creutzig U; Zimmermann M; Dworzak MN; Ritter J; Schellong G; Reinhardt D
    Klin Padiatr; 2013 May; 225 Suppl 1():S79-86. PubMed ID: 23700063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Hrstková H; Kopecná L; Tousovská K; Hak J; Procházková D; Cerná Z; Jabali Y; Timr P; Vávra V; Sedlácek P; Smísek P; Hrusák O; Michalová K
    Cas Lek Cesk; 2004; 143(4):257-63. PubMed ID: 15218726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aclacinomycin-A in the induction treatment of childhood AML.
    Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
    Onkologie; 1986 Jun; 9(3):154-5. PubMed ID: 3528963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
    Vormoor J; Ritter J; Creutzig U; Boos J; Heyen P; Ludwig WD; Harbott J; Löffler H; Schellong G
    Br J Cancer Suppl; 1992 Aug; 18():S63-7. PubMed ID: 1503929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].
    Creutzig U; Bender-Götze C; Klingebiel T; Ebell W; Friedrich W; Stollmann-Gibbels B; Schmidt H; Suttorp M; Gratwohl A; Heyen P
    Klin Padiatr; 1992; 204(4):246-52. PubMed ID: 1518260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].
    Ritter J; Creutzig U; Schellong G
    Onkologie; 1986 Apr; 9(2):78-82. PubMed ID: 3520425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.